{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:13Z","timestamp":1792802113994,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lungcan.2025.108579","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:24:21Z","timestamp":1746905061000},"page":"108579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"205","author":[{"given":"Natasha B.","family":"Leighl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Thayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Schnepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv J.","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2025.108579_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2025.108579_b0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108579_b0015","first-page":"100558","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR Exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"7878","key":"10.1016\/j.lungcan.2025.108579_b0020","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108579_b0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108579_b0030","unstructured":"RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; Revised September 2024."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108579_b0035","first-page":"421","article-title":"Progression of central nervous system metastases in advanced nonsmall cell lung cancer patients effectively treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.lungcan.2025.108579_b0040","doi-asserted-by":"crossref","unstructured":"A. Passaro, J. Wang, Y. Wang, S.H. Lee, B. Melosky, J.Y. Shih, J. Wang, K. Azuma, O. Juan-Vidal, M. Cobo, E. Felip, N. Girard, A.B. Cortot, R. Califano, F. Cappuzzo, S. Owen, S. Popat, J.L. Tan, J. Salinas, P. Tomasini, R.D. Gentzler, W.N. William Jr., K.L. Reckamp, T. Takahashi, S. Ganguly, D.M. Kowalski, A. Bearz, M. MacKean, P. Barala, A.B. Bourla, A. Girvin, J. Greger, D. Millington, M. Withelder, J. Xie, T. Sun, S. Shah, B. Diorio, R.E. Knoblauch, J.M. Bauml, R.G. Campelo, B.C. Cho; MARIPOSA-2 Investigators, Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study, Ann. Oncol. 35 (1) (2023) 77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"10.1016\/j.lungcan.2025.108579_b0045","article-title":"Blood-brain barrier and brain structural changes in lung cancer patients with non-brain metastases","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108579_b0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fonc.2018.00414","article-title":"Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease","volume":"8","author":"Kamath","year":"2018","journal-title":"Front. Oncol."},{"issue":"30","key":"10.1016\/j.lungcan.2025.108579_b0055","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:49:01Z","timestamp":1752590941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":11,"alternative-id":["S0169500225004714"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108579","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108579"}}